ArticleACS medicinal chemistry letters2021
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.
Open access · greenAbstract read
In one paragraph
Article in ACS medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 56 citations in OpenAlex.
- Recent Advances in the Design of Inhibitors Targeting the Viral Entry and Replication of the SARS-CoV-2 Virus, Driven by In Silico Approaches.Molecules (Basel, Switzerland) · 2026Review
- A Novel Covalent Inhibitor Fragment for the SARS-CoV-2 Main Protease Identified by Target-Specific Deep Learning.ACS chemical biology · 2026Article
- A Reflection on the Use of Molecular Simulation to Respond to SARS-CoV-2 Pandemic Threats.The journal of physical chemistry letters · 2025Review
- Exploring Possible Drug-Resistant Variants of SARS-CoV-2 Main Protease (MACS bio & med chem Au · 2025Article
- FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry.Frontiers in pharmacology · 2025Article
- Exploring the key structural attributes and chemico-biological interactions of pyridinone-based SARS-CoV-2 3CLHeliyon · 2024Article
- Design and synthesis of novel main protease inhibitors of COVID-19: quinoxalino[2,1-RSC advances · 2024Article
- Proof-of-concept studies with a computationally designed MProceedings of the National Academy of Sciences of the United States of America · 2024Article
- On the origins of SARS-CoV-2 main protease inhibitors.RSC medicinal chemistry · 2024Review
- Review
- A Comprehensive Update of Anti-COVID-19 Activity of Heterocyclic Compounds.Drug design, development and therapy · 2024Review
- Article
- Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.European journal of medicinal chemistry · 2023Review
- Preparing for the next pandemic.Science (New York, N.Y.) · 2023Article
- Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 MACS medicinal chemistry letters · 2023Article
- Integrated data-driven and experimental approaches to accelerate lead optimization targeting SARS-CoV-2 main protease.Journal of computer-aided molecular design · 2023Article
- Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors.Protein science : a publication of the Protein Society · 2023Article
- Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase.Journal of medicinal chemistry · 2023Article
- Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses.European journal of medicinal chemistry · 2023Article
- Recent PELE Developments and Applications in Drug Discovery Campaigns.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Chun-Hui ZhangDepartment of Chemistry, Yale University, New Haven, Connecticut 06520-8107, United States.
Krasimir A SpasovDepartment of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, United States.
Raquel A ReillyDepartment of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, United States.
Klarissa HollanderDepartment of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, United States.
Elizabeth A StoneDepartment of Chemistry, Yale University, New Haven, Connecticut 06520-8107, United States.ORCID https://orcid.org/0000-0002-2253-3452
Joseph A IppolitoDepartment of Chemistry, Yale University, New Haven, Connecticut 06520-8107, United States.
Maria-Elena LiosiDepartment of Chemistry, Yale University, New Haven, Connecticut 06520-8107, United States.
Maya G DeshmukhDepartment of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, United States.ORCID https://orcid.org/0000-0002-3704-3229
Julian Tirado-RivesDepartment of Chemistry, Yale University, New Haven, Connecticut 06520-8107, United States.ORCID https://orcid.org/0000-0001-7330-189X
Shuo ZhangDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut 06536-0812, United States.
Zhuobin LiangDepartment of Molecular, Cellular, and Developmental Biology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, United States.
Scott J MillerDepartment of Chemistry, Yale University, New Haven, Connecticut 06520-8107, United States.ORCID https://orcid.org/0000-0001-7817-1318
Farren IsaacsDepartment of Molecular, Cellular, and Developmental Biology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, United States.ORCID https://orcid.org/0000-0001-8615-8236
Brett D LindenbachDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut 06536-0812, United States.
Karen S AndersonDepartment of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520-8066, United States.ORCID https://orcid.org/0000-0003-3433-0780
William L JorgensenDepartment of Chemistry, Yale University, New Haven, Connecticut 06520-8107, United States.ORCID https://orcid.org/0000-0002-3993-9520
Yale University · US
Funding
X-ray Scattering Technology CoreP30GM133893 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI Sean McSweeney · 2019 to 2026
$38.6MUser Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI Nozomi Ando, J Christopher Fromme · 2018 to 2026
$34.2MMedical Scientist Training ProgramT32GM136651 · NIGMS · YALE UNIVERSITY · PI BARBARA I KAZMIERCZAK · 2020 to 2026
$16.5MPREDOCTORAL PROGRAM IN BIOPHYSICST32GM008283 · NIGMS · YALE UNIVERSITY · PI XIONG, YONG · 1988 to 2022
$10.5MPOTENTIAL FUNCTIONS FOR WATER PROTEIN INTERACTIONSR01GM032136 · NIGMS · YALE UNIVERSITY · PI JORGENSEN, WILLIAM L. · 1985 to 2023
$8.2MSite-Selective Catalysis for Bioactive Scaffold DiversificationR35GM132092 · NIGMS · YALE UNIVERSITY · PI Scott J Miller · 2019 to 2026
$6.3MINSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDT32GM007324 · NIGMS · YALE UNIVERSITY · PI BENNETT, ANTON M · 1987 to 2022
$6.2MMolecular determinants of hepatitis C virus assemblyR01AI087925 · NIAID · YALE UNIVERSITY · PI LINDENBACH, BRETT D. · 2010 to 2020
$4.1MPredoctoral Program in BiophysicsT32GM149438 · NIGMS · YALE UNIVERSITY · PI Yong Xiong, Elsa Chui Ying Yan · 2023 to 2026
$2.6MPixel Array Detector for Macromolecular CrystallographyS10OD021527 · OD · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2016 to 2016
$2.0MUpgrade of a home source macromolecular X-ray diffraction system.S10OD018007 · OD · YALE UNIVERSITY · PI BOGGON, TITUS JONATHON · 2014 to 2014
$460kNIAID NIH HHS R01 AI087925NIGMS NIH HHS P30 GM124165NIGMS NIH HHS P30 GM133893NIGMS NIH HHS R01 GM032136NIGMS NIH HHS R35 GM132092NIGMS NIH HHS T32 GM007324NIGMS NIH HHS T32 GM008283NIGMS NIH HHS T32 GM136651NIGMS NIH HHS T32 GM149438NIH HHS S10 OD018007NIH HHS S10 OD021527
Abstract
Non-covalent inhibitors of the main protease (M
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.